Table 4.
Different types of miRNA-mediated therapeutic approaches for breast cancer.
| Sl.No. | miRNAs | Used model | Therapeutics | Type of cancer | Reference |
|---|---|---|---|---|---|
| 1 | Nanoparticle (AuNPs) delivery of miRNA-708 mimetic | MDA-MB-231 cells and Xenograft model(CB-17 SCID mice and CB17 | Tumor suppression | Breast cancer | Ramchandani et al. (2019) |
| 2 | 1626 miRNA combination with trastuzumab and lapatinib | HER2 + breast cancer cell lines | Tumor suppression | Breast cancer | Normann et al. (2021) |
| 3 | miRNA-155 Antisense Oligonucleotide | MDA-MB-157 cell line and xenografting mouse model (4-week-old male BALB/c athymic nude mice) | Tumor suppression | Breast cancer | Zheng et al. (2013) |
| 4 | miRNA-26a/26b | MDA-MB-231, MCF-7 and human epithelial breast cell line MCF-10A and Female athymic nude mice (aged 4–6 weeks) |
Tumor suppression | Breast cancer | Ma et al. (2016) |
| 5 | miRNA-124 | MCF-7 and MDAMB-231 and 293T cell line and female athymic BALB/c nude mice (4 weeks old) | Tumor suppression | Breast cancer | Yan et al. (2019) |
| 6 | miRNA-34a silences C-SRC | Breast cancer cell lines and 5-to-6-week-old female CrTac; NCr-Foxn1 nu mice (Taconic) | Tumor suppression | Breast cancer | Adams et al. (2016) |
| 7 | miRNA-451 agomir | Drug resistance in breast cancer cell lines and in xenograft model | Tumor suppression | Breast cancer | Wang et al. (2017) |
| 8 | miRNA-3613-3p | MDA-MB-231 and MCF-7 and Female NOD/SCID mice, 6–8 weeks of age | Tumor suppression | Breast cancer | Chen et al. (2021) |
| 9 | Polymer Nanoparticles MediatedCo-Delivery (antisense-miRNA-21 and antisense-miRNA-10b loaded PLGA-b-PEG polymer NPs)of AntimiRNA-10b and AntimiRNA-21 | MDA-MB-231 cell line and xenograft model (female nude mice) | Tumor suppression | Breast cancer | Devulapally et al. (2015) |
| 10 | miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy | MCF-7 cell line | Tumor suppression | Breast cancer | Gao et al. (2015) |
| 11 | Expression of miRNA-200c | In vivo (wild-type Balb/c recipient mice.) | Tumor suppression | Breast cancer | Knezevic et al. (2015) |
| 12 | miRNA-497 | T-74D, MCF-7, MDA-MB-453, MDA-MB-468 and MDA-MB-435 cell line and male athymic BALB/c nu/nu mice (4–6 weeks old) | Tumor suppression | Breast cancer | Wu et al. (2016) |
| 13 | miRNA-603 | MCF-10A, TNBC, MDA-MB-436, MDA-MB-231, MDA-MB-468, BT-549, BT-20 cell lines and xenograft tumor model (Athymic female nude mice (4–5 weeks old) | Tumor suppression | Breast cancer | Bayraktar et al. (2017) |
| 14 | miRNA-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells |
BCSCs and mouse xenograft (NSG mice) | Tumor suppression | Breast cancer | De Cola et al., 2018 |
| 15 | miRNA-7-5p | BT549, MDA-MB-231,MDA-MB-468, MCF7, SK-BR-3, T47D, HBL100, and MCF-10A cell line and in vivo (nude mice) | Tumor suppression | Breast cancer | Shi et al. (2015) |
| 16 | miRNA-10b | Luciferase-expressing 4T1-Red-Fluc breast cancer cell line, derived originally from mouse mammary gland adenocarcino and eight-week-old female Balb/c mice | Tumor suppression | Breast cancer | Yoo et al. (2017) |
| 17 | miRNA-4306 | ZR-75-1, MCF-7, T47D, SK-BR-3, HCC1937, MDA-MB-468, MDA-MB-231 and CAL-51 cell line and four-week-old female BALB/c nude mice | Tumor suppression | Breast cancer | Zhao et al. (2019) |
| 18 | DOX + tRNA-miRNA-34a/POEG-PCre | In vitro and in vivo female BALB/c mice (4–6 weeks) | Tumor suppression | Breast cancer | Xu et al. (2019) |